The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
 
Antonio D'Alessio
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - Roche
 
Bernardo Stefanini
No Relationships to Disclose
 
Julia Blanter
No Relationships to Disclose
 
Benjamin Adegbite
No Relationships to Disclose
 
Claudia A.M. Fulgenzi
No Relationships to Disclose
 
Ciro Celsa
Speakers' Bureau - AstraZeneca
 
Giulia F Manfredi
No Relationships to Disclose
 
Madhava Pai
No Relationships to Disclose
 
Robert D. Goldin
No Relationships to Disclose
 
Daniel Shu
No Relationships to Disclose
 
Yung-Yeh Su
No Relationships to Disclose
 
Marina Baretti
Consulting or Advisory Role - Exelixis; Incyte
 
Robert A. Anders
No Relationships to Disclose
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Chiun Hsu
No Relationships to Disclose
 
Thomas Urban Marron
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
Travel, Accommodations, Expenses - Abbvie; Genentech
 
David James Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Lift Biosciences; Mursla Bio; Roche/Genentech; Starpharma
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley